The DOI matches its Crossref record; 115 of the 117 references it cites were found in a registry or an index.
Screening for Pancreatic Cancer: Why, How, and Who?
Open accessAbstract
In Brief Pancreatic cancer is the fourth most common cause of cancer mortality in the United States, with 5-year survival rates for patients with resectable tumors ranging from 15% to 20%. However, most patients presenting with distant metastases, are not resectable, and have a 5-year survival rate of close to 0%. This demonstrates a need for improved screening to identify pancreatic cancer while the tumor is still localized and amenable to surgical resection. Studies of patients with pancreatic tumors incidentally diagnosed demonstrate longer median survival than tumors discovered only when the patient is symptomatic, suggesting that early detection may improve outcome. Recent evidence from genomic sequencing indicates a 15-year interval for genetic progression of pancreatic cancer from initiation to the metastatic stage, suggesting a sufficient window for early detection. Still, many challenges remain in implementing effective screening. Early diagnosis of pancreatic cancer relies on developing screening methodologies with highly sensitive and specific biomarkers and imaging modalities. It also depends on a better understanding of the risk factors and natural history of the disease to accurately identify high-risk groups that would be best served by screening. This review summarizes our current understanding of the biology of pancreatic cancer relevant to methods available for screening. At this time, given the lack of proven benefit in this disease, screening efforts should probably be undertaken in the context of prospective trials. Pancreatic adenocarcinoma is a largely fatal disease with increased survival for patients with localized disease compared with those with distant metastases. A critical evaluation of early detection strategies is presented in light of results from more common cancers. Improved outcomes may be attained by focusing screening on high-risk groups; however, these efforts are as yet unproven.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Screening individuals in high-risk groups increases the rate of detection and reduces false-positive results.8”
From Early detection of pancreatic cancer (2020) · cites this paper as [8]
In the citing paper
“Similarly, incidentally diagnosed pancreatic ductal adenocarcinoma (ie, discovered serendipitously while screening or checking for other diseases) is associated with longer median survival than pancreatic ductal adenocarcinoma that is diagnosed when patients have symptoms.8”
From Early detection of pancreatic cancer (2020) · cites this paper as [8]
In the citing paper
“Patients diagnosed with stage 1 disease experience longer survival times than patients diagnosed with disease at more advanced stages.8”
From Early detection of pancreatic cancer (2020) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer
Taylor, D. D., & Gerçel-Taylor, Ç. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.033 · Cited by 2,333
RetractedFOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Hospital Volume and Surgical Mortality in the United States
Birkmeyer, J. D., Siewers, A. E., Finlayson, E. V. A., Stukel, T. A., Lucas, F. L., Batista, I., Welch, H. G., & Wennberg, D. E. (2002) · New England Journal of Medicine · doi:10.1056/nejmsa012337 · Cited by 5,001
Skog, J., Würdinger, T., van Rijn, S., Meijer, D. H., Gainche, L., Curry, W. T., Carter, B. S., Krichevsky, A. M., & Breakefield, X. O. (2008) · Nature Cell Biology · doi:10.1038/ncb1800 · Cited by 5,001
Siegel, R. L., Ward, E., Brawley, O. W., & Jemal, A. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20121 · Cited by 4,075
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Reducing Mortality from Colorectal Cancer by Screening for Fecal Occult Blood
Mandel, J. S., Bond, J. H., Church, T. R., Snover, D. C., Bradley, G. M., Schuman, L. M., & Ederer, F. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305133281901 · Cited by 3,220
Randomised controlled trial of faecal-occult-blood screening for colorectal cancer
Hardcastle, J. D., Chamberlain, J., Robinson, M. H., Moss, S. M., Amar, S. S., Balfour, T. W., James, P., & Mangham, C. M. (1996) · The Lancet · doi:10.1016/s0140-6736(96)03386-7 · Cited by 2,784
Cited by
Sorted by citations
Items 201–255 of 255
Pankreaskarzinom – Screening oder Surveillance?
Sirtl, S., Vornhülz, M., Hofmann, F. O., Mayerle, J. V., & Beyer, G. (2023) · Die Radiologie · doi:10.1007/s00117-023-01227-3 · Cited by 2
Recent progress in microRNA detection using integrated electric fields and optical detection methods
Velmanickam, L., & Nawarathna, D. (2024) · Frontiers in Lab on a Chip Technologies · doi:10.3389/frlct.2024.1349384 · Cited by 2
Malpractice Claims Following Major Liver and Pancreatic Surgeries: What Can we Learn?
Zaman, M., Li, J. H., & Dhir, M. (2024) · Journal of Surgical Research · doi:10.1016/j.jss.2024.03.026 · Cited by 2
Lesmana, C. R. A., Gani, R. A., & Lesmana, L. A. (2017) · EMJ Gastroenterology · doi:10.33590/emjgastroenterol/10313857 · Cited by 2
Hereditary Pancreatic Cancer Syndromes: Providing Care to At-Risk Families
King, E., & Nehoray, B. (2019) · Clinical journal of oncology nursing · doi:10.1188/19.cjon.579-582 · Cited by 2
A multi-analyte serum biomarker panel for early detection of pancreatic adenocarcinomaPreprint
Firpo, M. A., Boucher, K. M., Bleicher, J. M., Khanderao, G. D., Rosati, A., Poruk, K. E., Kamal, S., Marzullo, L., Marco, M. D., Falco, A., et al. (2022) · medRxiv · doi:10.1101/2022.03.03.22271867 · Cited by 2
Self-citationMukherjee, M., Ghosh, S., Maity, A., Ray, S., Saha, H., Bahadur, R. P., & Goswami, S. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01363-7 · Cited by 1
Lin, W., Yu, L., Kuo, Y., Chang, C., Wang, H., Shih, S., Chang, C.-W., Lin, H., Chan, Y., Lin, Y., et al. (2025) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i11.112030 · Cited by 1
Systems Biology of Pancreatic Cancer Stem Cells
Bao, G. F., Philip, P. A., & Azmi, A. S. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-408103-1.00013-3 · Cited by 1
Secondary Screening for Inherited Pancreatic Ductal Adenocarcinoma
Sheel, A., Nicholson, J., Sarantitis, I., Neoptolemos, J. P., & Greenhalf, W. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_63 · Cited by 1
Malla, R. R., & Nagaraju, G. P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23523-8.00013-4 · Cited by 1
Elder, M. M., Mbous, Y. P. V., Rudisill, T. M., & Kelley, G. A. (2024) · Health Sciences Review · doi:10.1016/j.hsr.2024.100203 · Cited by 1
Screening Strategies for Pancreatic Cancer in High-Risk Patients
Talamonti, M. S. (2015) · JAMA Surgery · doi:10.1001/jamasurg.2015.0391 · Cited by 1
Label Free MicroRNA Biomarker Detection in Serum Samples for Diagnosis Applications at Point-of Care
Velmanickam, L., Pokharel, R., Lima, I. T., & Nawarathna, D. (2019) · IEEE Research and Applications of Photonics in Defense Conference (RAPID) · doi:10.1109/rapid.2019.8864379 · Cited by 1
Yan, F., Valerio, T. I., Sibichan, M., Chambers, K., Bishop, E., Wilson, T., Wang, C., Yan, Y., Hoover, A. R., Chen, W. R., et al. (2022) · doi:10.1117/12.2608348 · Cited by 1
Screening for Pancreatic Cancer: Current Status and Future Directions
Puri, A., Chang, J. C. S., & Kundranda, M. N. (2017) · European Medical Journal · doi:10.33590/emj/10313242 · Cited by 1
Zheng, Z., Chen, Z., Lin, Y., & Wei, J. (2023) · AIP Advances · doi:10.1063/5.0162189 · Cited by 1
Guest editorial: funding for innovative cancer-relevant technology development
Dickherber, A. J., Sorg, B. S., Divi, R. L., Ganguly, A., & Ossandon, M. R. (2014) · Lab on a Chip · doi:10.1039/c4lc90059f · Cited by 1
Gong, J., Li, X., Feng, Z., Lou, J., Pu, K., Sun, Y., Hu, S., Wu, J., & Wu, Y. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.20.549805 · Cited by 1
Pancreatic cancer: a review with future directions
Nehlsen, A. D., & Brady, L. W. (2016) · Journal of Radiation Oncology · doi:10.1007/s13566-016-0264-5
Secondary Screening for Inherited Pancreatic Ductal Adenocarcinoma
Sheel, A., Nicholson, J., Sarantitis, I., Neoptolemos, J. P., & Greenhalf, W. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_63-1
Xu, W., Jiang, B., & Yin, X. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s139938
Pancreatic Cancer Screening: Attempts and Possibilities
Mourad, M. M., Evans, R. P. T., Aly, E. A., Fisher, S. G., Dvorkin, L. S., & Bramhall, S. R. (2017) · Journal of Hepatology and Gastrointestinal disorders · doi:10.4172/2475-3181.1000151
Velmanickam, L. (2019) · NDSU Repository (North Dakota State University)
Delivery of Neoadjuvant Versus Adjuvant Therapy in Localized Pancreatic Cancer
George, B., & Ritch, P. S. (2019) · Springer eBooks · doi:10.1007/978-3-319-98944-0_7
Challenges and Opportunities for Early Pancreatic Cancer Detection: Role for Protein Biomarkers
Oldfield, L. S., Barrera, L. N., Williams, D., Evans, A., Neoptolemos, J. P., & Costello, E. (2020) · Molecular and translational medicine · doi:10.1007/978-3-030-49476-6_4
Molecular-targeted therapy of pancreatic carcinoma and its progress
Zhang, X., & Li, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819402-7.00020-6
Conversion Therapy of Unresectable Pancreatic Cancer: A Retrospective Study of the Real WorldPreprint
Wang, M., Zhu, P., Chen, Z., & Yang, L. (2021) · Research Square · doi:10.21203/rs.3.rs-674137/v1
Pankreaskarzinom – Screening oder Surveillance: Was ergibt Sinn?
Sirtl, S., Vornhülz, M., Hofmann, F. O., Mayerle, J. V., & Beyer, G. (2022) · Die Gastroenterologie · doi:10.1007/s11377-022-00652-5
Updates in The Role of MRI in Diagnosis and Staging of Pancreatic Cancer: A Systematic Review
Alkhalidy, A. J. S., Matabi, A. I. H., Rayshan, H. A. A., Hagawi, F. M., Alyami, M. S. M., Shami, D. T. I., Huraysi, W. M. J., Alsaadi, H. A. M., Alzamanan, M. N., & Bnisalman, H. S. H. (2022) · International Journal of Life Science and Pharma Research · doi:10.22376/ijlpr.2023.13.1.sp2.l66-l74
The Diagnostic Value of EUS-FNA in Occupying Lesions of Pancreatic Head Uncinate Process
赵, 春. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1351049
Rabab, S. A., Zaidi, S. M. F., Amjad, A., Paras, & Sattar, M. (2023) · Research Square · doi:10.21203/rs.3.rs-3748655/v1
Zhong, Z., Yang, J., Luo, J.-Z., Xie, X., Huang, Z., & Long, D. (2023) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000001
Pankreaskarzinom – Screening oder Surveillance: Was ergibt Sinn?
Sirtl, S., Vornhülz, M., Hofmann, F. O., Mayerle, J. V., & Beyer, G. (2024) · best practice onkologie · doi:10.1007/s11654-024-00556-6
Rabab, S. A., Zaidi, S. M. F., Amjad, A., Paras, & Sattar, M. (2024) · SAGE Open Medical Case Reports · doi:10.1177/2050313x241241197
Liu, P., Zu, F., Chen, H., Yin, X., & Tan, X. (2022) · Figshare · doi:10.6084/m9.figshare.21303027
Liu, P., Zu, F., Chen, H., Yin, X., & Tan, X. (2022) · Figshare · doi:10.6084/m9.figshare.21303018
Liu, P., Zu, F., Chen, H., Yin, X., & Tan, X. (2022) · Figshare · doi:10.6084/m9.figshare.21303024
Liu, P., Zu, F., Chen, H., Yin, X., & Tan, X. (2022) · Figshare · doi:10.6084/m9.figshare.21303015
Liu, P., Zu, F., Chen, H., Yin, X., & Tan, X. (2022) · Figshare · doi:10.6084/m9.figshare.21303033
Liu, P., Zu, F., Chen, H., Yin, X., & Tan, X. (2022) · Figshare · doi:10.6084/m9.figshare.21303030
An overview of imaging in pancreatic cancer
Mareddy, N. S. R., & Chakkera, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24742-2.00016-2
Possibilities for early detection of pancreatic cancer
Dosoudilová, M., Kasparova, K., Dolečková, Z., & Grodová, K. (2024) · Klinická biochemie a metabolismus · doi:10.61568/kbm.2024.013
Itoh, H., Asai, S., Takashimizu, S., Nakagohri, T., Nishizaki, Y., & Miyachi, H. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.100951
Policelli, R., Ward, A. D., Dammak, S., Kassam, Z., Ramsewak, D., Kalia, V., Nadrah, A., Wang, D., Madubuobi, H., Abbott, C. L., et al. (2025) · Current Problems in Diagnostic Radiology · doi:10.1067/j.cpradiol.2025.10.007
Liu, P., Zu, F., Chen, H., Yin, X., & Tan, X. (2022) · Figshare · doi:10.6084/m9.figshare.21303036
Liu, P., Zu, F., Chen, H., Yin, X., & Tan, X. (2022) · Figshare · doi:10.6084/m9.figshare.21303012
Li, S., Zhang, C., Lv, S., Zhang, Z., Xu, D., & Xu, T. (2026) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s562602
Risk factors and some aspects of pancreatic cancer prevention
Павловна, Б. А., Kozlova, I. V., Андреевна, Т. Т., Пахомова, А. Л., & Лекарева, Л. И. (2026) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-244-12-103-112
Unravelling the pathogenesis and therapeutic approaches of pancreatic ductal adenocarcinoma
Roy, I., & Thakur, R. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04289-6
How are pancreatic tumors innervated?
Nguyen, T. T. H. (2017) · doi:10.70675/cddec815z4e10z4727z99cez3311438335a2
Ciblage pharmacologique du microenvironnement de l'adénocarcinome canalaire pancréatique
Samain, R. (2018) · theses.fr (ABES) · doi:10.70675/e35639a1z6534z4cb6z9efbza38473efebed
Molins, E. A. G. (2020) · theses.fr (ABES) · doi:10.70675/252d1be2z22e8z4378zb146zfd4ec7fa46a7
Souche, F.-R. (2021) · theses.fr (ABES) · doi:10.70675/9c3ebbe0zf293z4cebz8008zded4724282b7
Youssef, C., Day, C., Spaulding, A., Verastegui, A., Tice, M. P., Thiels, C. A., Fong, Z. V., Stauffer, J. A., & Poruk, K. E. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01545-4
Self-citation
Metadata
- Authors
- Poruk, K. E., Firpo, M. A., Adler, D. G., & Mulvihill, S. J.
- Affiliations
- University of Utah (US)
- Corresponding author
- Poruk, Katherine E.
- Venue
- Annals of Surgery
- Published
- 2013-01
- Volume
- 257
- Issue
- 1
- Pages
- 17-26
- ISSN
- 0003-4932 (ISSN-L)
- PMC
- PMC4113008
- OpenAlex
- W2050410927
- Cited by
- 249
- References
- 117
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 16 · 2023: 25 · 2022: 33 · 2021: 16 · 2020: 24 · 2019: 25 · 2018: 14 · 2017: 25 · 2016: 18 · 2015: 15 · 2014: 15 · 2013: 4
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Annals of Surgery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (T35HL007744)
- National Cancer Institute (U01CA151650, R03CA115225, U01CA15165, R33CA155586, P30CA042014)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Keywords
- pancreatic cancer, cancer screening, early detection, pancreatic ductal adenocarcinoma, biomarkers, imaging modalities, high-risk groups, risk factors, natural history of disease, resectability, survival
- MeSH terms
- Adenocarcinoma, Humans, Magnetic Resonance Imaging, Pancreatic Neoplasms, Precancerous Conditions, Risk Factors, Sensitivity and Specificity, Tomography, X-Ray Computed, Biomarkers, Tumor, United States, Endosonography, Early Detection of Cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
